MLTX (MoonLake Immunotherapeutics Class A Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by MLTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-29 | Kristian Reich | Chief Scientific Officer | Sell | — | — |
| 2026-07-23 | Kristian Reich | Chief Scientific Officer | Sell | — | — |
| 2026-07-21 | Kristian Reich | Chief Scientific Officer | Sell | — | — |
| 2026-07-20 | Kristian Reich | Chief Scientific Officer | Sell | — | — |
| 2026-07-13 | da Silva Jorge Santos | Chief Executive Officer | Sell | — | — |
| 2026-07-02 | da Silva Jorge Santos | Chief Executive Officer | Sell | — | — |
| 2026-06-23 | Matthias Bodenstedt | Chief Financial Officer | Sell | — | — |
| 2026-06-22 | BVF INC/IL | Director | A | — | — |
| 2026-06-18 | Catherine Moukheibir | Director | A | — | — |
| 2026-06-18 | Ramnik Xavier | Director | A | — | — |
| 2026-06-18 | Matthias Bodenstedt | Chief Financial Officer | Sell | — | — |
| 2026-06-18 | Spike Loy | Director | A | — | — |
| 2026-06-18 | Andrew John Phillips | Director | A | — | — |
| 2026-06-17 | Kristian Reich | Chief Scientific Officer | Sell | — | — |
| 2026-05-13 | Matthias Bodenstedt | Chief Financial Officer | Sell | — | — |
| 2026-04-16 | Matthias Bodenstedt | Chief Financial Officer | Sell | — | — |
| 2026-04-14 | da Silva Jorge Santos | Chief Executive Officer | Sell | — | — |
| 2026-04-10 | Matthias Bodenstedt | Chief Financial Officer | Sell | — | — |
| 2026-04-02 | BIOTECHNOLOGY VALUE FUND L P | Director | Sell | — | — |
| 2026-01-09 | Kristian Reich | Chief Scientific Officer | A | — | — |
| 2026-01-09 | da Silva Jorge Santos | Chief Executive Officer | A | — | — |
| 2026-01-09 | Matthias Bodenstedt | Chief Financial Officer | A | — | — |
| 2025-12-22 | Kristian Reich | Chief Scientific Officer | MIXED | — | — |
| 2025-12-22 | Matthias Bodenstedt | Chief Financial Officer | MIXED | — | — |
| 2025-12-22 | da Silva Jorge Santos | Chief Executive Officer | MIXED | — | — |
| 2025-12-10 | da Silva Jorge Santos | Chief Executive Officer | Sell | — | — |
| 2025-12-10 | Kristian Reich | Chief Scientific Officer | Sell | — | — |
| 2025-10-09 | Matthias Bodenstedt | Chief Financial Officer | Buy | — | — |
| 2025-10-01 | Bihua Chen | — | Sell | — | — |
| 2025-09-04 | Kristian Reich | Chief Scientific Officer | MIXED | — | — |
| 2025-07-07 | Catherine Moukheibir | Director | MIXED | — | — |
| 2025-06-09 | Ramnik Xavier | Director | A | — | — |
| 2025-06-09 | Andrew John Phillips | Director | A | — | — |
| 2025-06-09 | Simon Sturge | Director | A | — | — |
| 2025-06-09 | Spike Loy | Director | A | — | — |
| 2025-06-09 | Catherine Moukheibir | Director | A | — | — |
| 2025-06-09 | BIOTECHNOLOGY VALUE FUND II LP | Director | A | — | — |
| 2025-03-03 | Kristian Reich | Chief Scientific Officer | A | — | — |
| 2025-03-03 | Matthias Bodenstedt | Chief Financial Officer | A | — | — |
| 2025-03-03 | da Silva Jorge Santos | Chief Executive Officer | A | — | — |
| 2025-01-22 | Kristian Reich | Chief Scientific Officer | MIXED | — | — |
| 2024-10-08 | Simon Sturge | Director | Sell | — | — |
| 2024-10-08 | BIOTECHNOLOGY VALUE FUND L P | Director | Sell | — | — |
| 2024-06-10 | BVF PARTNERS L P/IL | Director | A | — | — |
| 2024-06-07 | Andrew John Phillips | Director | A | — | — |
| 2024-06-07 | Spike Loy | Director | A | — | — |
| 2024-06-07 | Simon Sturge | Director | A | — | — |
| 2024-06-07 | Ramnik Xavier | Director | A | — | — |
| 2024-06-07 | Catherine Moukheibir | Director | A | — | — |
| 2024-02-29 | da Silva Jorge Santos | Chief Executive Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 11,265,678 | — |
| — | Director | 10,235,089 | — |
| — | Director | 9,005,700 | — |
| — | 10%+ Owner | 8,367,498 | — |
| — | Director | 8,302,735 | — |
| — | Director | 6,599,722 | — |
| — | — | 3,215,000 | — |
| — | Chief Executive Officer | 2,843,182 | — |
| — | Chief Scientific Officer | 2,746,587 | — |
| — | 10%+ Owner | 1,994,173 | — |
| — | Chief Financial Officer | 1,115,435 | — |
| — | Director | 171,980 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MLTX quote page; the site-wide leaderboard is on the insider transactions hub.